Therapeutic Potential of Cannabinoids in Schizophrenia

J 2014

Therapeutic Potential of Cannabinoids in Schizophrenia

KUČEROVÁ, Jana, Katarína TABIOVÁ, Filippo DRAGO a Vincenzo MICALE

Základní údaje

Originální název

Therapeutic Potential of Cannabinoids in Schizophrenia

Autoři

KUČEROVÁ, Jana (203 Česká republika, garant, domácí), Katarína TABIOVÁ (703 Slovensko, domácí), Filippo DRAGO (380 Itálie) a Vincenzo MICALE (380 Itálie, domácí)

Vydání

Recent Patents on CNS Drug Discovery, Nizozemsko, Bentham Science Publishers B.V. 2014, 1574-8898

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Kód RIV

RIV/00216224:14740/14:00075476

Organizační jednotka

Středoevropský technologický institut

DOI

http://dx.doi.org/10.2174/1574889809666140307115532

Klíčová slova anglicky

delta 9-tetrahydrocannabinol; animal models; antipsychotics; cannabidiol; cannabis; CB receptors; endocannabinoid system; schizophrenia

Štítky

kontrola MP, ok, rivok, SCOPUS, WOS

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 28. 4. 2015 21:56, Martina Prášilová

Anotace

V originále

Increasing evidence suggests a close relationship between the endocannabinoid system and schizophrenia. The endocannabinoid system comprises of two G protein-coupled receptors (the cannabinoid receptors 1 and 2 [CB1 and CB2] for marijuana's psychoactive principle delta 9-tetrahydrocannabinol), their endogenous small lipid ligands (namely anandamide [AEA] and 2-arachidonoylglycerol [2-AG], also known as endocannabinoids), and proteins for endocannabinoid biosynthesis and degradation. It has been suggested to be a pro-homeostatic and pleiotropic signalling system activated in a time- and tissue-specific manner during pathophysiological conditions. In the brain, activation of this system impacts the release of numerous neurotransmitters in various systems and cytokines from glial cells. Hence, the endocannabinoid system is strongly involved in neuropsychiatric disorders, such as schizophrenia. Therefore, adolescence use of Cannabis may alter the endocannabinoid signalling and pose a potential environmental risk to develop psychosis. Consistently, preclinical and clinical studies have found a dysregulation in the endocannabinoid system such as changed expression of CB1 and CB2 receptors or altered levels of AEA and 2-AG . Thus, due to the partial efficacy of actual antipsychotics, compounds which modulate this system may provide a novel therapeutic target for the treatment of schizophrenia. The present article reviews current available knowledge on herbal, synthetic and endogenous cannabinoids with respect to the modulation of schizophrenic symptomatology. Furthermore, this review will be highlighting the therapeutic potential of cannabinoid-related compounds and presenting some promising patents targeting potential treatment options for schizophrenia.

Návaznosti

ED1.1.00/02.0068, projekt VaV

Název: CEITEC - central european institute of technology

Citovat

KUČEROVÁ, Jana, Katarína TABIOVÁ, Filippo DRAGO a Vincenzo MICALE. Therapeutic Potential of Cannabinoids in Schizophrenia. Recent Patents on CNS Drug Discovery. Nizozemsko: Bentham Science Publishers B.V., 2014, roč. 9, č. 1, s. 13-25. ISSN 1574-8898. Dostupné z: https://dx.doi.org/10.2174/1574889809666140307115532.

@article{1182619,
   author = {Kučerová, Jana and Tabiová, Katarína and Drago, Filippo and Micale, Vincenzo},
   article_location = {Nizozemsko},
   article_number = {1},
   doi = {http://dx.doi.org/10.2174/1574889809666140307115532},
   keywords = {delta 9-tetrahydrocannabinol; animal models; antipsychotics; cannabidiol; cannabis; CB receptors; endocannabinoid system; schizophrenia},
   language = {eng},
   issn = {1574-8898},
   journal = {Recent Patents on CNS Drug Discovery},
   title = {Therapeutic Potential of Cannabinoids in Schizophrenia},
   url = {http://www.eurekaselect.com/120809/article},
   volume = {9},
   year = {2014}
}

TY  - JOUR
ID  - 1182619
AU  - Kučerová, Jana - Tabiová, Katarína - Drago, Filippo - Micale, Vincenzo
PY  - 2014
TI  - Therapeutic Potential of Cannabinoids in Schizophrenia
JF  - Recent Patents on CNS Drug Discovery
VL  - 9
IS  - 1
SP  - 13-25
EP  - 13-25
PB  - Bentham Science Publishers B.V.
SN  - 15748898
KW  - delta 9-tetrahydrocannabinol
KW  - animal models
KW  - antipsychotics
KW  - cannabidiol
KW  - cannabis
KW  - CB receptors
KW  - endocannabinoid system
KW  - schizophrenia
UR  - http://www.eurekaselect.com/120809/article
L2  - http://www.eurekaselect.com/120809/article
N2  - Increasing evidence suggests a close relationship between the endocannabinoid system and schizophrenia. The endocannabinoid system comprises of two G protein-coupled receptors (the cannabinoid receptors 1 and 2 [CB1 and CB2] for marijuana's psychoactive principle delta 9-tetrahydrocannabinol), their endogenous small lipid ligands (namely anandamide [AEA] and 2-arachidonoylglycerol [2-AG], also known as endocannabinoids), and proteins for endocannabinoid biosynthesis and degradation. It has been suggested to be a pro-homeostatic and pleiotropic signalling system activated in a time- and tissue-specific manner during pathophysiological conditions. In the brain, activation of this system impacts the release of numerous neurotransmitters in various systems and cytokines from glial cells. Hence, the endocannabinoid system is strongly involved in neuropsychiatric disorders, such as schizophrenia. Therefore, adolescence use of Cannabis may alter the endocannabinoid signalling and pose a potential environmental risk to develop psychosis. Consistently, preclinical and clinical studies have found a dysregulation in the endocannabinoid system such as changed expression of CB1 and CB2 receptors or altered levels of AEA and 2-AG . Thus, due to the partial efficacy of actual antipsychotics, compounds which modulate this system may provide a novel therapeutic target for the treatment of schizophrenia. The present article reviews current available knowledge on herbal, synthetic and endogenous cannabinoids with respect to the modulation of schizophrenic symptomatology. Furthermore, this review will be highlighting the therapeutic potential of cannabinoid-related compounds and presenting some promising patents targeting potential treatment options for schizophrenia.
ER  -

KUČEROVÁ, Jana, Katarína TABIOVÁ, Filippo DRAGO a Vincenzo MICALE. Therapeutic Potential of Cannabinoids in Schizophrenia. \textit{Recent Patents on CNS Drug Discovery}. Nizozemsko: Bentham Science Publishers B.V., 2014, roč.~9, č.~1, s.~13-25. ISSN~1574-8898. Dostupné z: https://dx.doi.org/10.2174/1574889809666140307115532.

Podrobný výpis o publikaci